Welcome
To Research in Statistics, Mathematics, and SAS programming
We have technical expertise in Statistical Analysis Plan, Reporting and interpreting analysis results, SAS programming, and Validation of TFLs (Safety and Efficacy tables, figures, listings using SAS or S-Plus/R.) for clinical trials in phases I-IV. We have expertise in most of therapeutic areas and our specialties are Oncology, Osteoporosis, Diabetes, Alzheimer's disease and Cardiovascular. We have over 20 years of pharmaceutical experiences and clinical data manipulation. We had played great role in number of successful NDA submissions within pharmaceutical industries. We are familiar with FDA requirements and knowledgeable of drug approval process, ICH guidelines, GCP, and EMEA. We can take your clinical trial studies to a successful FDA submission using CRT (Case Report Tabulation) for electronic submissions, implementing SOPs and Working Guidelines.
To discuss more in detail how we can help you to reach to your successful FDA submissions, please get in touch with us.
Articles to consider for Clinical Trial Design
|
About 10000 clinical trials are undertaken annually in all
areas of medicine, from the treatment of acne to the
prevention of cancer. Correct interpretation of the data
from such trials depends largely on adequate design and on
performing the appropriate statistical analyses. The
statistical aspects of both the design and analysis of
trials are important, with particular emphasis on recently
developed methods of analysis.
|
1. Guidance for determining the number of centers in clinical trials
2. Guidelines on Data Safety and Monitoring
This guideline is to provide the oversight and necessity of interim monitoring to ensure the safety of the study participants and the validity and integrity of the trial data. Phase III clinical trials usually have a Data and Safety monitoring Board (DSMB), with broad responsibility for monitoring the conduct of the trial.
3. Guidelines for the Creation of Analysis Data Files and Documentation of Statistical Analyses for Submission
4. Guidance for Contents of the Clinical Study Report
The purpose of this document is to provide guidelines on what information need to be included in statistical section of the Clinical Study Report (CSR).
5. Guidance for Non-Inferiority Clinical Trials
6. Fundamentals of Biostatistics ( 1. Clinical Trials (RCT), 2. Validity/Reliability, 3. Assessing Evidence)
Oncology: Optimal Two-Stage Designs For Phase II Clinical Trials
Example of this Calculation
| Optimal Two Stage Design | Optimum Design | MinMax Design |
|---|---|---|
| First Stage Sample Size (n1) | ||
| Upper Limit For 1st Stage Rejection of Drug (r1) | ||
| Maximum Sample Size (n) | ||
| Upper Limit for 2nd Stage Rejection of Drug (r) | ||
| Expected Sample Size If Response Probability = P0 | ||
| Probability of Early Termination at P0 |
Simple Directory
Manufacturers
Submit your URL to a
quality web directory
FREE URL Submission - Submit your site to dozens of top search engines for FREE. No strings attached! Mathematics Directory Askbee directory LinkBook GreatDir.com A Web Directory K-Links Directory Sanory Directory
SAS Copyright ? 2003 by SAS Institute Inc., Cary, NC, USA. All rights reserved.
Copyright 2006 All Rights Reserved ? All the artwork appearing in this eDavar web are copyrighted to the stated artist and web Designer.
Publisher & Author:
Davar (Dave) Hamadani
/ Executive Director/Biostatistician
